Your browser doesn't support javascript.
loading
Incidence of Lyme Borreliosis in Germany: A retrospective observational healthcare claims study.
Brestrich, Gordon; Hagemann, Christine; Diesing, Joanna; Kossack, Nils; Stark, James H; Pilz, Andreas; Angulo, Frederick J; Yu, Holly; Suess, Jochen.
Afiliação
  • Brestrich G; Pfizer Pharma GmbH, Berlin, Germany. Electronic address: Gordon.brestrich@pfizer.com.
  • Hagemann C; Pfizer Pharma GmbH, Berlin, Germany.
  • Diesing J; Scientific Institute for Health Economics and Health System Research (WIG2 GmbH), Germany.
  • Kossack N; Scientific Institute for Health Economics and Health System Research (WIG2 GmbH), Germany.
  • Stark JH; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Cambridge, MA, USA.
  • Pilz A; Pfizer Corporation GmbH, Vienna, Austria.
  • Angulo FJ; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, Pennsylvania, USA.
  • Yu H; Health Economics and Outcomes Research, Pfizer Biopharma Group, Collegeville, Pennsylvania, USA.
  • Suess J; Brehm Memorial Center (BREHM WORLD), Renthendorf, Germany.
Ticks Tick Borne Dis ; 15(3): 102326, 2024 May.
Article em En | MEDLINE | ID: mdl-38417196
ABSTRACT
Lyme borreliosis (LB) is the most common tick-borne disease in Germany. Although the incidence of LB in Germany has been assessed in several studies, those studies either used data from statutory surveillance, which frequently underreport cases, or data from health claims databases, which may overestimate cases due to non-specific LB case definitions. Here, using a more specific case definition, we describe the incidence of medically-attended LB by disease manifestation, age group, and federal state for the period 2015-2019. Both inpatient and outpatient cases were analyzed from a claims database. To be eligible for inclusion, patients were required to have an LB specific ICD-10 GM diagnosis code plus an antibiotic prescription, and for disseminated manifestations, a laboratory test order additionally. LB cases were classified as erythema migrans (EM), or disseminated disease including Lyme arthritis (LA), Lyme neuroborreliosis (LNB), and all other disease manifestations (OTH). Between 2015 and 2019, the incidence of medically-attended LB cases ranged from 195.7/100,000 population per year (95% confidence interval [CI], 191.0 - 200.5) to 254.5/100,000 population per year (95% CI, 249.0 - 260.0) per year. The majority of cases (92.2%) were EM, while 2.8% presented as LA, 3.8% as LNB, and 1.2% as OTH. For both EM and disseminated disease, the incidence peaked in children aged 5-9 years and in older adults. By federal state, the incidence of medically-attended EM ranged from 74.4/100,000 population per year (95% CI, 71.9 - 77.0) per year in Hamburg, to 394.1/100,000 population per year (95% CI, 370.7 - 417.6) per year in Saxony, whereas for medically-attended disseminated disease, the highest incidence was in Thuringia, Saxony, and Bavaria (range 22.0 [95% CI, 19.9 - 24.0] to 35.7 [95% CI, 34.7 - 36.7] per 100,000 population per year). This study comprehensively estimated the incidence of all manifestations of medically-attended LB and showed a high incidence of LB throughout Germany. Results from the study support performing epidemiological studies in all federal states to measure the burden of LB and to invest in public health interventions for prevention.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Lyme / Eritema Migrans Crônico / Neuroborreliose de Lyme Limite: Aged / Child / Humans País/Região como assunto: Europa Idioma: En Revista: Ticks Tick Borne Dis Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Lyme / Eritema Migrans Crônico / Neuroborreliose de Lyme Limite: Aged / Child / Humans País/Região como assunto: Europa Idioma: En Revista: Ticks Tick Borne Dis Ano de publicação: 2024 Tipo de documento: Article